Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2
- 13 November 2002
- journal article
- research article
- Published by Elsevier
- Vol. 11 (6) , 629-636
- https://doi.org/10.1016/0264-410x(93)90308-k
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- A novel strategy for converting recombinant viral protein into high immunogenic antigenFEBS Letters, 1991
- Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal modelsVaccine, 1991
- Efficacy of Recombinant Glycoprotein D Subunit Vaccines on the Development of Primary, Recurrent, and Latent Genital Infections with Herpes Simplex Virus Type 2 in Guinea PigsThe Journal of Infectious Diseases, 1988
- Herpes Simplex Virus Glycoprotein Treatment of Recurrent Genital HerpesThe Journal of Infectious Diseases, 1988
- The quest for a herpes simplex virus vaccine: background and recent developmentsVaccine, 1986
- Acute Genital Infection in Guinea Pigs: Effect of Recombinant Interleukin-2 on Herpes Simplex Virus Type 2The Journal of Infectious Diseases, 1986
- Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus‐specific glycoproteins gB or gDJournal of Medical Virology, 1985
- Vaccinia Virus Recombinant Expressing Herpes Simplex Virus Type 1 Glycoprotein D Prevents Latent Herpes in MiceScience, 1985
- Protection from Genital Herpes Simplex Virus Type 2 Infection by Vaccination with Cloned Type 1 Glycoprotein DScience, 1985
- Protection of Mice from Lethal Herpes Simplex Virus Infection by Vaccination with a Secreted form of Cloned Glycoprotein DNature Biotechnology, 1984